Neuspera Medical has released 12-month pivotal trial results for its integrated sacral neuromodulation system, a battery-free implantable device for urinary urge incontinence that transfers power wirelessly from an external wearable. The trial enrolled 128 patients across U.S. and European sites, and the data were presented at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting in late February 2026. Separately, the company disclosed preliminary findings from a reduced-duration therapy protocol, suggesting that just 30 minutes of daily stimulation may achieve outcomes comparable to longer sessions.
Why durability at 12 months changes the competitive calculus for sacral neuromodulation devices
The headline figure, 94% of test-phase responders achieving at least a 50% reduction in urinary urge incontinence episodes, is clinically meaningful but needs to be read carefully. The denominator here is test-phase responders, not the full implanted population. This is standard practice in sacral neuromodulation trials, where a percutaneous test phase filters patients before permanent implant, but it creates an important distinction when comparing across platforms. The figure most relevant to clinicians comparing device options is the responder rate from the full implanted cohort, which remains the appropriate benchmark for long-term therapy durability.
Within the responder population, 81% achieved at least 75% symptom reduction, classified as super-responders, and 43% reported complete dryness at 12 months. These outcomes, if sustained through longer follow-up, position the Neuspera system competitively against established platforms from Medtronic and Axonics. Both competitors have extensive real-world datasets and reimbursement pathways that a relatively newer entrant does not yet possess at comparable scale. Longevity data beyond 12 months will be necessary before most health technology assessment bodies would treat this system as equivalent.
How the battery-free design addresses a structural vulnerability in existing SNM platforms
The defining technical differentiation here is not the stimulation efficacy, which is broadly comparable to existing sacral neuromodulation systems, but rather the elimination of the implanted battery. Conventional SNM devices require battery replacement surgeries every three to five years, depending on usage parameters, and each revision procedure carries infection risk, anaesthesia exposure, and healthcare cost. The Neuspera system externalises the power source entirely, with the implanted neurostimulator drawing energy from a wearable disc during a daily therapy session.
This architecture is particularly relevant in the current clinical environment given the rapid uptake of GLP-1 receptor agonists for weight management. Significant weight loss in patients who carry subcutaneous implanted pulse generators can alter device positioning, affect tissue contact, and in some cases precipitate revision surgery. The Neuspera system’s miniaturised implant profile reduces this exposure. Industry observers tracking SNM adoption note that as GLP-1 prescribing continues to expand, device manufacturers with battery-dependent architectures may face a growing subset of patients at elevated revision risk, making battery-free designs more attractive to both clinicians and payers over time.
The zero-infection rate through 12 months is a meaningful safety signal, though trial populations tend to reflect more controlled conditions than real-world clinical practice. Infection rates in conventional SNM are typically low but not negligible, and a single-digit incident rate in a commercially deployed population would already be considered favourable. The absence of serious device-related adverse events in this trial cohort is encouraging, but the trial size of 128 implanted patients is modest relative to the post-market datasets that support competitor labelling.
What the 30-minute stimulation protocol reveals about the therapy mechanism and patient burden
The secondary finding, that a 30-minute daily stimulation session produced UUI episode reductions of 73% to 100% in early-stage patients, has implications that extend beyond patient convenience. If a compressed stimulation window can replicate outcomes from longer sessions, it suggests that sacral neuromodulation in this system operates more through neuromodulatory priming than through sustained electrical suppression. That interpretation, if confirmed in larger and longer studies, would support a therapeutic model where periodic stimulation recalibrates neural pathways rather than continuously inhibiting unwanted detrusor contractions.
The clinical implications are substantial. Reduced daily therapy burden could improve adherence in real-world practice, where patients may struggle to maintain consistent long-duration sessions. It also simplifies the patient experience around device charging and wearable use. However, this data represents one-month outcomes in a small initial cohort and should not be extrapolated to conclusions about long-term equivalence. Neuspera has indicated it will present additional data at the American Urological Association Annual Meeting later in 2026, which will provide a clearer picture of whether the benefit is durable over time or whether it reflects a transient early response.
Regulatory position, commercialisation runway, and what adoption actually requires
The Neuspera system received FDA approval in June 2025, placing it approximately 25 years behind Medtronic’s InterStim, which has been commercially available since 1997, and several years behind Axonics, which entered the U.S. market in 2019. Approval is necessary but not sufficient for meaningful adoption. Sacral neuromodulation is a procedurally intensive therapy, and implanting physicians require training and credentialling before they can perform procedures independently. Building a trained implanter network takes time and substantial field clinical investment.
Reimbursement coverage for the Neuspera system will follow established SNM billing codes, which simplifies the payer pathway relative to a novel therapy category. However, commercial coverage for newer device entrants often carries utilisation management requirements or prior authorisation criteria that can slow case volume in early market phases. Regulatory watchers note that the clean safety profile, with zero infections and no serious device-related adverse events, strengthens the reimbursement narrative but does not eliminate the institutional inertia that favours established platforms in high-volume SNM programmes.
The competitive landscape is also evolving. Axonics was acquired by Boston Scientific in 2023, giving it access to a large urology sales force and integrated account relationships that an independent company like Neuspera cannot replicate without significant partnership or capital investment. Medtronic continues to dominate SNM market share and recently updated its InterStim platform with rechargeable options that partially address the battery revision burden. The Neuspera system’s full-externalisation of power delivery remains structurally distinct, but clinicians and procurement committees will weigh this against the track record and servicing infrastructure that established players offer.
What clinicians and regulators will watch next
The most important near-term data event is the AUA presentation on reduced-duration therapy. If those results hold across a larger patient sample and a longer observation window, it would meaningfully differentiate the system’s patient burden profile. Beyond that, the field will look for two-year and three-year data to confirm durability, real-world infection and revision rates as commercial implantation scales, and comparative data against established systems from prospective or registry-based studies. Whether Neuspera pursues additional indications, including faecal incontinence or urgency-frequency without incontinence, both of which are approved indications for existing SNM platforms, will also signal how the company intends to build its clinical footprint and justify the infrastructure investment required to compete at scale.
What Neuspera’s 12-month iSNM trial data means for the sacral neuromodulation competitive landscape added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →